Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership
UK-based Enara Bio has entered into a collaboration with German-headquartered Boehringer Ingelheim. Under the terms of the deal, Enara will...
UK-based Enara Bio has entered into a collaboration with German-headquartered Boehringer Ingelheim. Under the terms of the deal, Enara will...
Ensure your company's deals are accurately presented to thousands of potential clients by using our deals submission form.
Consolidation in the pharmaceutical sector, with the biggest November deals happening in the US, was given a boost by China last month.
DNA damage response (DDR)-focused Artios Pharma has signed a global strategic collaboration with the Merck Group to discover and develop multiple precision cancer drugs.
Precision medicine-focused Frontier Medicines has signed a multi-year collaboration with AbbVie to discover, develop and commercialise multiple small molecule therapeutics against difficult-to-drug protein targets.
UK-based artificial intelligence (AI) drug discovery company Exscientia has received a $4.2m two-year grant from the Bill and Melinda Gates Foundation to apply its two Centaur platforms to three global...
Swiss-based Noema Pharma has raised CHF54m ($60.8m) in an oversubscribed Series A round. The funding was co-led by Sofinnova Partners and Polaris Partners; other investors included Gilde Healthcare and BioMed...
Founded in the 1990s, the Novo Nordisk Foundation oversees the management and administration of the Novo Group, comprised of Novo Nordisk, the Danish pharma giant renowned for its diabetes research and products,...
Dublin-based biopharma company SynOx has secured €37m in a Series A financing round led by HealthCap and Medicxi. Forbion and Gimv also participated in the financing.
US rare disease-focused biotech BioMarin has entered a preclinical collaboration with Toronto-based artificial intelligence (AI) company Deep Genomics to discover and develop oligonucleotide drug candidates for four undisclosed rare diseases...
Pharma giant Merck has entered into a definitive agreement to acquire oncology biotech VelosBio for $2.75bn in cash. The acquisition remains subject to certain customary adjustments and conditions; the deal...
Approved in May 2019 for children under two with spinal muscular atrophy (SMA), Novartis’s Zolgensma (onasemnogene abeparvovec) is a transformative, one-time gene therapy that targets the genetic cause of SMA....